Clinical trials: Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma in Relapse, Multiple Myeloma
Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
Pomalidomide either as single therapy or in combination with cyclophosphamide, elotuzumab, bortezomib, or daratumumab are effective treatment regimens in relapsed refractory multiple myeloma (RRMM).
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory
- Trial name
- POMAlternative (NCT05555329)
- Testing
- Pomalidomide 4 mg every day in cycle 1, Pomalidomide 4 mg every other day in cycle 2, Pomalidomide 2 mg every day in cycle 2
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Myeloma
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
This is an open-label, multicenter clinical trial designed to evaluate the safety and potential efficacy of venetoclax and ABBV-838 combination therapy with dexamethasone in participants with relapsed or refractory multiple…
- Trial name
- NCT02951117
- Testing
- Venetoclax, ABBV-838, Dexamethasone
- Where
- 3 sites in Australia
- Sponsor
- AbbVie
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Research question: Is KRd therapy effective and safe in the real-world Asian patients? Primay objective: To evaluate the effectiveness of KRd in RRMM patients Secondary objectives: To evaluate the effectiveness of investigational…
- Trial name
- NCT05495620
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Volunteers
- 300 people
- Sponsor
- Dong-A University Hospital
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Multiple Myeloma
A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the tolerability and safety of subcutaneous (SC) delivery of co-formulated daratumumab and rHuPH20 preparation (DARA SC) in Japanese participants with relapsed or refractory multiple…
- Trial name
- NCT03242889
- Testing
- DARA SC
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma and Plasma Cell Neoplasm
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00558896
- Testing
- dexamethasone, pomalidomide
- Where
- 3 sites in United States
- Volunteers
- 378 people
- Sponsor
- Mayo Clinic
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Multiple Myeloma, Relapsed/Refractory
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
This is a phase 2 study to see how effective investigational drug, JNJ-42756493, is when given in combination with dexamethasone in two groups of patients with multiple myeloma (cancer of the plasma cells, a type of white blood…
- Trial name
- NCT02952573
- Testing
- JNJ-42756493, Dexamethasone
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00096096
- Testing
- mycophenolate mofetil, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Multiple Myeloma
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01155583
- Testing
- azacitidine, lenalidomide, dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM)
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.
- Conditions
- Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT02265731
- Testing
- azacitadine, venetoclax, rituximab / IDEC-C2B8
- Where
- 14 sites in Japan
- Volunteers
- 38 people
- Sponsor
- AbbVie
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
This is a phase I clinical study to evaluate the safety and tolerability of C-4-29 in patients with relapsed or refractory multiple myeloma, and to obtain the maximum tolerated dose of C-4-29 and phase II Recommended dose.
- Trial name
- NCT04861480
- Testing
- C-4-29 Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Multiple Myeloma
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT01522872
- Testing
- TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Threshold Pharmaceuticals
Multiple Myeloma
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- NCT05372354
- Testing
- CC-92480, Tazemetostat, BMS-986158
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate tolerability of the combination therapy of JNS002 and bortezomib in Japanese bortezomib-naive patients with multiple myeloma who have ever received at least 1 line of chemotherapy.
- Trial name
- NCT01371227
- Testing
- JNS002
- Where
- 2 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma (MM), Cancer
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT04178902
- Testing
- ABBV-467
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 8 people
- Sponsor
- AbbVie
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even…
- Trial name
- LMY-920-002 (NCT05546723)
- Testing
- Autologous CAR-T cell therapy expressing the BAFF-ligand.
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Luminary Therapeutics
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins